enterprise p&t meeting committee meeting minutes april 30 ......mike colvin, pharmd jamila...
TRANSCRIPT
Voting Members Present
Enterprise P&T Meeting Committee Meeting Minutes
April 30, 2018
David Batluck, DO Gus Geraci, MD Chris Meny, RPh Andrew Peterson, PharmD Rodney Wise, MD
Donald Beam, MD Glenn Hamilton, MD Jay Messeroff, RPh David Petkash, MD
William Burnham, MD Fred Hill, MD Kendra Michael, M Jeanine Plante, PharmD
Kirt Caton, MD Jeffrey Kreitman, PharmD Betty Muller, MD Kirby Smith, MD
Don Cooper, RPh Markus Kruesi, MD Lavdena Orr, MD Wayne Weart, PharmD
Rogers Elebra, PharmD Susan McAllister, MD Eric Peters, PharmD Rani Whitfield. MD
Excused Voting Members
John Floyd Brinley, MD Lily Higgins, MD Melissa Rooney, RN Jen Devinney, PharmD Parul Mistry, MD Rajiv Vyas, MD
Invited Guests Present
Linda Albandoz, NCPhT - PRx April Holly - LDH Kelly Martin, PharmD Paul Larry, DMD Corp Dental Director
Kathleen Clement, Administrative- PRx Matt Hassel, Administrative- PRx Lauren Megargell, PharmD-PRx Mariel Shull, PharmD-PRx
Mike Colvin, PharmD Jamila Jorden, PharmD - PRx Tim Melancon, Sparks Therapeutics Devon Trumbower, PharmD-PRx Tracy Davis, PharmD -DC Paul Knecht, PharmD Holly Moreau, Prestige Calla Vodoor – PharmD Patrick DeHoratius, PharmD - PRx Lanaye Lawyer, MD Michelle Murphy, PharmD Pharmacy Director Melwyn Wendt, PharmD Fury Fecondo, PharmD Shalis. Lightner, Pharmacy Manager Herbert Peeples, PharmD
25
Issue
Discussion
Conclusion/ Results
Vote
Action/ Person Responsible
1. Call to Order
The meeting was called to order at 6:00 PM EST. Dr. Burnham welcomed all new of our external and internal participants.
Informational Only
Dr. William Burnham
2. Conflict of Interest Disclosures
Dr. Burnham if anyone has a conflict of interest to disclose that would recuse them from voting on any agenda item.
Informational Only
Dr. William Burnham
3. ACLA Common PDL Attestation
Informational Only
Kelly Martin
4. Review of last P&T Minutes
Kelly Martin asked if there were any corrections or updates to the minutes from January 29, 2018. Attendee Correction: Mel Wendt from LDH instead of Doug Wendt from Merck
Informational Only
Kelly Martin
5. Proxy Minutes
Proxy email sent 2/20/2018 Informational
Only Kelly Martin
SHSC – SA Opioid PA Criteria SHSC – LA Opioid PA Criteria
Recommendation to add the following line items: 1. Greater than 1 opioid prescription per 30 days is medically necessary. 2. The diagnosis is for pain uncontrolled by non-opioid medications. Recommendation to approve the newly developedLA Opioid Criteria
Informational Only
Kelly Martin
26
Issue
Discussion
Conclusion/ Results
Vote
Action/ Person Responsible
6. Old Business
Inhaled Corticosteroids (ICS)
PerformRx makes the following recommendation:Remove Dulera from the formulary for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA. a. Members 9 years of age or older currently on this product will be converted to either Breo Ellipta or generic Airduo Respiclick. b. Members 8 years of age or younger will be allowed to obtain Dulera without the need of a prior authorization Make no other changes to the formulary status of any other products within this class.
Committee approved as recommended
25-0
GLP-1 Agonists
PerformRx makes the following recommendation: Add Ozempic to the formulary for KF/AHC/AHN/CHC, AHDC and SHSC with a step therapy requirement of a prior trial of a metformin product. Remove Victoza from the formulary for KF/AHC/AHN/CHC, AHDC and SHSC. No indefinite grandfathering, with members currently on Victoza converted to either Trulicity or Ozempic. Add Ozempic to the formulary for ACLA without any step therapy requirement. Make no other changes to the formulary status of any other product in this class.
Add Ozempic KF/AHC/AHN/ CHC, AHDC and SHSC formularywith step therapy. Add to ACLA formulary with no step therapy
25-0 PerformRx will update the criteria and formulary/PDL with any changes
27
Issue
Discussion
Conclusion/ Results
Vote
Action/ Person Responsible
SHSC- Banzel PerformRx makes the following recommendation: Retire the criteria and making Banzel formulary/preferred with step therapy with another formulary/preferred anticonvulsant medication, age limit of greater than 1year old and ICD-10 codes (listed below) to process at the point of sale for SHSC. ICD_10 Code –Code Description o G40.811 – Lennox-Gastaut syndrome, not intractable, with status epilepticus o G40.812- Lennox-Gastaut syndrome, not intractable, without status epilepticus o G40.813- Lennox-Gastaut syndrome, intractable, with status epilepticus o G40.814- Lennox-Gastaut syndrome, intractable, without status epilepticus
Committee approved as recommended 25-0
PerformRx will update the criteria and formulary/PDL with any changes
SHSC - Dostinex
PerformRx makes the following recommendation: Retire the criteria and making Dostinex formulary/preferred with step therapy with bromocriptine along with an ICD-10 code (see below) processed at the point of sale for SHSC. ICD_10 Code –Code Description o E22.1- Hyperprolactinemia
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
28
Issue
Discussion
Conclusion/ Results
Vote
Action/ Person Responsible
CNS Stimulants Age Limit PA Criteria (ACLA)
PerformRx makes the following recommendation: Approve the updated criteria for ACLA to clearly define what Metadate ER tablets products are preferred. In addition, adding missing products from the Non- Preferred section.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Cystic Fibrosis Oral Agents PA Criteria
PerformRx makes the following recommendation: Approve the oral cystic fibrosis criteria with the addition of Symdeko for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Lemtrada
PerformRx makes the following recommendation: Approve the updated prior authorization criteria forKF/AHC/AHN/CHC, AHDC, SHSC, and ACLA with the removal of ECG requirement as it is no longer recommended in labeling. Approve the criteria for BCC with the following change: included all formulary products as prerequisite option.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Opioid PA Criteria- SHSC
PerformRx makes the following recommendation: Add prior authorization criteria to limit member to one long-acting opioid fill per 30 days.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
Hepatitis C PA Criteria- AHDC
PerformRx makes the following recommendation: Change fibrosis score coverage from F2-F4 and now allow F0-F4 fibrosis coverage
Informational Only
PerformRx will update the criteria and formulary/PDL with any changes
29
Issue
Discussion
Conclusion/ Results
Vote
Action/ Person Responsible
Hepatitis C PA Criteria- AHDC
PerformRx makes the following recommendation: Change fibrosis score coverage from F2-F4 and now allow F0-F4 fibrosis coverage
Informational Only
PerformRx will update the criteria and formulary/PDL with any changes
Tysabri
PerformRx makes the following recommendation: Approve the criteria for BCC with the following change: addition of all formulary products as possible pre-requisite options.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
7. New Business
Opioid containing cough/cold medication age limits
PerformRx makes the following recommendation: Add the age limits listed below to KF/AHC/CHC, AHN, AHDC, SHSC and ACLA & BCC a. Codeine products in combination with antihistamines or decongestants (i.e. promethazine with codeine, guaifenesin with codeine etc.)- change the age limit from 12 years of age, to only allowing these products to pay in members 18 years of age and older. b. Hydrocodone products in combination with antihistamines or decongestants (i.e. Tussionex)- Add an age limit only allowing it to pay in members 18 and older products.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
Guanylate Cyclase-C Receptor Agonists Criteria- BCC
PerformRx makes the following recommendation: Approve this newly-created criteria for BCC to more effectively manage requests for this drug class.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
30
Issue
Discussion
Conclusion/ Results
Vote Action/ Person Responsible
Lidoderm PA Criteria - BCC
PerformRx makes the following recommendation: Approve this newly developed criteria for BCC
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Weight Loss Medications SHSC – Informational Only
PerformRx makes the following recommendation: Approve the updated criteria to ensure compliance with state requirements that only 2 products (Alli &Xenical) are eligible for coverage.
Informational Only
PerformRx will update the criteria and formulary/PDL with any changes.
8. Drug Reviews Therapeutic Classes:
.
Oral Antihistamine Agents
PerformRx makes the following recommendation: Removing promethazine vials from the formulary for KF/AHC/AHN/CHC, AHDC, SHSC and ACLARemoving clemastine from the formulary for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA Remove carbinoxamine 4mg tablets from the formulary for SHSC Add chlorpheniramine 4mg tablets to the formularyfor AHDC, ACLA and SHSC Add diphenhydramine 25mg tablets and capsules to the formulary for ACLA.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Selective serotonin Reuptake Inhibitors
PerformRx makes the following recommendation: Add generic Prozac 40mg capsule to the formulary for SHSC Remove Lexapro solution from formulary with indefinite grandfathering for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA Remove Celexa solution from formulary with indefinite grandfathering for KF/AHC/AHN/CHC, AHDC, and SHSC Remove Paxil CR from the formulary with indefinite grandfathering for AHDC, SHSC and ACLA
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
31
Issue Discussion Conclusion/ Results Vote Action/ Person Responsible
Contraceptive Devices Condoms/Diaphrams
PerformRx makes the following recommendation: Make no changes to the formulary status of the products within this class.
Committee approved as recommended
25-0 No Changes
Gaucher Disease with PA Criteria
PerformRx makes the following recommendation: Approve the updated Gaucher’s Disease Treatment Agents Prior Authorization Criteria for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA. Make no changes to the formulary status of the products within this class.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Short Acting Insulins PerformRx makes the following recommendation: Add Admelog and Admelog Solostar to the formulary for KF/AHC/AHN /CHC, AHDC, SHSC, ACLA and BCC with a quantity limit of 30mls per 30 days for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA. Admelog vial will be added to the formulary with a quantity limit of 60 ml/30 days and Admelog Solostar will be added to the formulary with a quantity limit of 30 ml/30 days for BCC. Remove Humalog vials/Kwikpen/cartridge, Apidra and Apidra Solostar from the formulary for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA. Convert members on Humalog vials / Kwikpen /cartridge, Apidra or Apidra Solostar to either Admelog or Admelog Solostar. No indefinite grandfathering for these members. Remove Novolog Flexpen and Novolog from the formulary for SHSC and ACLA. Convert members to either Admelog or Admelog Solostar. No indefinite grandfathering for members on Novolog Flexpen or Novolog. Make no other changes to the formulary status of any other product within this class.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
32
Issue Discussion Conclusion/ Results Vote Action/ Person Responsible
SGLT-2 Inhibitors
PerformRx makes the following recommendation: Add Steglatro and Segluromet to the formulary for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA with step therapy requirements. Members must have a previous trial of a metformin product in their history before Steglatro and Segluromet will pay at the point of sale. Add Steglatro and Segluromet to the formulary with prior authorization for BCC. Make no other changes to the formulary status of any other products within this class.
Committee approved, requested we speak to prior authorization team if Jardiance product line is asked for CVD, it is approved and the Steglatro product line is not required first.
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Single Product Reviews:
Entresto
PerformRx makes the following recommendation: Add Entresto to the formulary for KF/AC/AHN/CHC, AHDC, SHSC and ACLA Retire the drug specific prior authorization criteria.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Bidil
PerformRx makes the following recommendation: Add Bidil to the formulary for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
Ridaura
PerformRx makes the following recommendation: Make no changes to the formulary status of Ridauraat this time
Committee approved as recommended
25-0 No Changes
33
Issue Discussion Conclusion/ Results Vote Action/ Person Responsible
Luxturna
PerformRx makes the following recommendation: Make no changes to the formulary status of Luxturna at this time.
Committee approved as recommended
25-0 No Changes
Provenge
PerformRx makes the following recommendation: Make no changes to the formulary status of Provenge at this time
Committee approved as recommended
25-0 No Changes
Symfi Lo
PerformRx makes the following recommendation: Add Symfi and Symfi Lo to the formulary for KF/AHC/AHN/CHC and SHSC.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
New Products Reviews
PerformRx makes the following recommendation: Add to the formulary for KF/AHC/AHN/CHC, AHDC. Already on formulary for SHSC and ACLA Eliquis Zenpep Add to the formulary for KF/AHC/AHN/CHC and SHSC Already added to the formulary for ACLA Symfi Lo Add to the formulary with step therapy for ACLA Segluromet Steglatro Add to the formulary for ACLA Ozempic Add to the formulary with step therapy for KF/AHC/AHN/CHC, AHDC and SHSC Ozempic Segluromet Steglatro
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
34
Issue Discussion Conclusion/ Results Vote Action/ Person Responsible
New Products Reviews… continued
Remain Non-Formulary for KF/AHC/AHN/CHC, AHDC and SHSC. Add to formulary for ACLA Trogarzo
Remain Non-Formulary for KF/AHC/AHN/CHC, AHDC and SHSC. Already on formulary for ACLA Biktarvy
Remain Non-Formulary & use drug specific PA Criteria for KF/AHC/AHN/CHC, AHDC. Already on formulary with ST For SHSC and ACLA Daliresp
Remain Non-Formulary & use drug specific PA Criteria, already on formulary for ACLA Makena Quick- Shot AutoInjector Remain Non-Formulary & use drug specific PA Criteria Alunbrig Bosulif Endari Erleada Imbruvica Lyrica CR Opdivo Sublocade Symdeko Trisenox Remain Non-Formulary Adzenys ER Bonjesta Clenpiq Clinimix DicloPR DiThol Fibryga Firvanq Giapreza Heplisav-B Impoyz
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
35
Issue Discussion Conclusion/ Results Vote Action/ Person Responsible
New Products Reviews… continued
Remain Non-Formulary Lonhala Lutathera Luxturna Nipride RTU Noctiva Odactra Prolastin-C Sinuva Steglujan Solosec Tisseel Xigduo XR
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
9. Prior Authorization Criteria Review Specialty Drugs - Existing:
Acthar
PerformRx makes the following recommendation: Maintain the current criteria for KF/AHC/ AHN/CHC, AHDC, SHSC and ACLA with no changes.
Committee approved as recommended
25-0 No Changes
Ampyra
PerformRx makes the following recommendation: Maintain the current criteria for KF/AHC/AHN /CHC, AHDC, SHSC and ACLA with no changes.
Committee approved as recommended
25-0 No Changes
Epogen
PerformRx makes the following recommendation: Maintain the current criteria for KF/AHC/AHN/ CHC, AHDC, SHSC and ACLA.
Committee approved as recommended
25-0 No Changes
Erythropoiesis Stimulating Agents
PerformRx makes the following recommendations: Maintain the current criteria for KF/AHC/AHN/ CHC, AHDC, SHSC and ACLA with no changes
Committee approved as recommended
25-0 No Changes
36
Issue Discussion Conclusion/ Results Vote Action/ Person Responsible
9. Prior Authorization Criteria Review Specialty Drugs - Existing:
Hep C- ACLA only
PerformRx makes the following changes: Approve the prior authorization criteria for ACLA with the following changes: Removed Fibroscan and added FibroSure/FibroTest as a means of determining fibrosis level, removed drug testing and specific timeframe for sobriety, changed to attestation that patient is not actively abusing, removed provider restriction to be in compliance with directive from state.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Kuvan
PerformRx makes the following changes: Approve the criteria with the removal of Phe restricted diet in the reauthorization sections and adding clarification on the Phe level results requiredfor reauthorization for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
Oncology without specific criteria
PerformRx makes the following changes: Maintain the current criteria for KF/AHC/AHN/ CHC, AHDC, SHSC, ACLA and BCC with no changes.
Committee approved as recommended
25-0 No Changes
Rituxan
PerformRx makes the following changes: Approve the updated prior authorization criteria forKF/AHC/AHN/CHC, AHDC, SHSC and ACLA with the following changes: o The addition of Rituxan Hycela o The removal of a glucocorticoid and azathioprine as prerequisite therapy for GPA or MPA and the addition of a nephrologist as an accepted prescriber for these indications.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Soliris
PerformRx makes the following recommendation: Approve this updated prior authorization criteria forKF/AHC/AHN/CHC, AHDC, SHSC and ACLA with the addition of the new indication of Myasthenia Gravis and specific criteria and updating general criteria for all other FDA labeled indications
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
37
Issue Discussion Conclusion/ Results Vote Action/ Person Responsible9. Prior Authorization Criteria Review Specialty Drugs - Existing:
Long acting injectable antipsychotics
PerformRx makes the following changes: Approve the updated prior authorization criteria forKF/AHC/AHN/CHC, AHDC, SHSC and ACLA with the following changes: removed requirement that member has noncompliance issues and has failed adherence measures to improve.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Specialty Drugs New:
Amyotrophic Lateral Sclerosis Agents\
PerformRx makes the following recommendation: Approve this newly-created criteria for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA to ensure appropriate approval of these agents.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Non-Specialty - Existing:
Buprenorphine products
PerformRx makes the following recommendation: Approve the criteria for BCC with no changes.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Non-Formulary PA Criteria
PerformRx makes the following recommendation: Change the reviewer note to refer to the Brand name medication criteria as the Medwatch criteria is now retired for ACLA and adapting for AHDC. Change the reviewer note to refer to the Brand name medication criteria as the Medwatch criteria is now retired for Keystone First, AmeriHealth Caritas, AmeriHealth Northeast and Community Health Choices, BCC and retiring for AmeriHealth DC. Change the reviewer note to refer to the Brand name medication criteria as the Medwatch criteria is now retired for SHSC
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
38
Issue Discussion Conclusion/ Results Vote Action/ Person ResponsibleNon-Specialty - Existing: Opioid Containing Products
PerformRx makes the following recommendation: Approve the criteria with changes associated with state mandated edits and to help facilitate in the review process for KF/AHC/AHN/CHC. Approve the criteria with minor updates for AHDC
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Opioid Dependence Agents
PerformRx makes the following recommendation: Approve the criteria with changes associated with state mandated edits and to help facilitate in the review process for KF/AHC/AHN/CHC
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes.
Lidoderm
PerformRx makes the following recommendation: Approve the Lidoderm prior authorization criteria without any changes for KF/AHC/AHN/CHC, AHDC, ACLA and SHSC.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
Mepron
PerformRx makes the following recommendation: Approve the Mepron prior authorization criteria without any changes for KF/AHC/AHN/CHC, AHDC, SHSC and ACLA.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
Multaq
PerformRx makes the following recommendation: Approve the Multaq prior authorization criteria with the appropriate changes for KF/AHC/AHN/CHC, AHDC, BCC, ACLA and SHSC. PerformRx recommends adding criteria for which members a negative pregnancy test is/is not warranted.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
Serotonin Receptor Agonists (Triptans)
PerformRx makes the following recommendation: Approve the Serotonin Receptor Agonists (Triptans) prior authorization criteria with the appropriate changes (the removal of Zecuity which is no longer available) for KF/AHC/AHN/CHC, AHDC, and SHSC. Approve the Serotonin Receptor Agonists (Triptans) prior authorization criteria with the appropriate changes (the removal of Zecuity which is no longer available) for ACLA.
Committee approved as recommended
25-0 PerformRx will update the criteria and
formulary/PDL with any changes
39
Issue Discussion Conclusion/ Results Vote Action/ Person ResponsibleNon-Specialty - Existing: Zyvox
PerformRx makes the following recommendation: Maintain the current criteria for KF/AHC/AHN CHC, AHDC, ACLA and SHSC with no changes.
Committee approved as recommended
25-0 No Changes
Lyrica and Lyrica CR
PerformRx makes the following recommendation: Approve the Lyrica prior authorization criteria with the addition of the newly approved Lyrica CR and placement of this product with its FDA approved indication of use for KF/AHC/AHN/CHC, AHDC, and SHSC. Approve the Lyrica prior authorization criteria with the addition of the newly approved Lyrica CR and placement of this product with its FDA approved indication of use for ACLA.
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
Pediculicides
PerformRx makes the following recommendation: Approve the Pediculicides prior authorization criteria without any changes for KF/AHC/AHN /CHC, AHDC, ACLA and SHSC.
Committee approved as recommended. Sklice is preferred for KF/AHC/AHN/ CHC with no ST requirement
25-0 PerformRx will update the criteria and formulary/PDL with any changes
Skeletal Muscle Relaxants
PerformRx makes the following recommendation: Maintain the current criteria for SHSC and ACLA with no changes
Committee approved as recommended
25-0 No Changes
Qualaquin
PerformRx makes the following recommendation: Maintain the current criteria for SHSC, ACLA, and BCC with no changes.
Committee approved as recommended
25-0 No Changes
Sporanox
PerformRx makes the following recommendation: Maintain the current criteria for ACLA and SHSC with no changes.
Committee approved as recommended
25-0 No Changes
40
Issue Discussion Conclusion/ Results Vote Action/ Person Responsible
Non-Specialty - New:
Formulary Medications with Diagnosis Code Requirement
PerformRx makes the following recommendation: Approve the criteria Diagnosis Code Requirement for KF/AHC/AHN/CHC, AHDC and SHSC
Committee approved as recommended
25-0 PerformRx will update the criteria and formulary/PDL with any changes
10. DTM Program Description
Overview of DTM program Description provided.
Informational Only PerformRx
11. Recalls
Zinbryta Voluntary Market Removal
SHSC 2 members notified BCC 2 members notified ACLA 0 members notified Prestige 1 member notified There were no other Non-lot level recalls to address
Informational
Shalis Lightner
Jeff Kreitman
12. Adjournment
The meeting adjourned at 7:47 PM EST
N/A
The next meeting August 6, 2018from 6:00 PM‐ 8:00 PM.
Dr. William Burnham, MD - Chair Date
41